Prelude Therapeutics Incorporated (NASDAQ:PRLD - Get Free Report) CFO Bryant David Lim acquired 25,000 shares of the stock in a transaction on Thursday, December 19th. The shares were purchased at an average cost of $0.91 per share, with a total value of $22,750.00. Following the transaction, the chief financial officer now directly owns 27,400 shares of the company's stock, valued at approximately $24,934. This trade represents a 1,041.67 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
Prelude Therapeutics Stock Performance
Shares of NASDAQ:PRLD traded up $0.41 during trading on Friday, reaching $1.30. 4,433,679 shares of the stock traded hands, compared to its average volume of 205,806. The stock has a market cap of $71.55 million, a P/E ratio of -0.73 and a beta of 1.49. The stock has a 50-day moving average of $1.21 and a two-hundred day moving average of $3.17. Prelude Therapeutics Incorporated has a 52-week low of $0.80 and a 52-week high of $6.80.
Prelude Therapeutics (NASDAQ:PRLD - Get Free Report) last issued its earnings results on Wednesday, November 6th. The company reported ($0.43) EPS for the quarter, beating the consensus estimate of ($0.48) by $0.05. The business had revenue of $3.00 million for the quarter. Sell-side analysts expect that Prelude Therapeutics Incorporated will post -1.81 earnings per share for the current year.
Wall Street Analyst Weigh In
Several research firms recently weighed in on PRLD. HC Wainwright restated a "buy" rating and issued a $5.00 price target on shares of Prelude Therapeutics in a research note on Friday, November 8th. JMP Securities reissued a "market outperform" rating and issued a $4.00 target price (down from $7.00) on shares of Prelude Therapeutics in a research note on Wednesday, December 11th.
View Our Latest Stock Report on PRLD
Institutional Investors Weigh In On Prelude Therapeutics
Several large investors have recently bought and sold shares of the business. Jacobs Levy Equity Management Inc. lifted its holdings in shares of Prelude Therapeutics by 885.2% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 174,979 shares of the company's stock valued at $362,000 after buying an additional 157,218 shares during the period. State Street Corp increased its position in Prelude Therapeutics by 35.1% during the third quarter. State Street Corp now owns 286,046 shares of the company's stock valued at $592,000 after acquiring an additional 74,300 shares during the last quarter. Walleye Capital LLC increased its position in Prelude Therapeutics by 446.2% during the third quarter. Walleye Capital LLC now owns 83,175 shares of the company's stock valued at $172,000 after acquiring an additional 67,946 shares during the last quarter. XTX Topco Ltd bought a new position in Prelude Therapeutics in the third quarter valued at about $100,000. Finally, Geode Capital Management LLC boosted its position in Prelude Therapeutics by 8.2% in the third quarter. Geode Capital Management LLC now owns 391,716 shares of the company's stock worth $811,000 after purchasing an additional 29,765 shares during the last quarter. 79.72% of the stock is currently owned by institutional investors.
About Prelude Therapeutics
(
Get Free Report)
Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion.
Recommended Stories
Before you consider Prelude Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prelude Therapeutics wasn't on the list.
While Prelude Therapeutics currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
